Mucopolysaccharidosis-Plus Syndrome: Report on a Polish Patient with a Novel VPS33A Variant with Comparison with Other Described Patients

Int J Mol Sci. 2022 Sep 28;23(19):11424. doi: 10.3390/ijms231911424.

Abstract

Eleven patients from Yakutia with a new lysosomal disease assumed then as mucopolysaccharidosis-plus syndrome (MPS-PS) were reported by Gurinova et al. in 2014. Up to now, a total number of 39 patients have been reported; in all of them, the c.1492C>T (p.Arg498Trp) variant of the VPS33A gene was detected. Here, we describe the first Polish MPS-PS patient with a novel homozygous c.599G>C (p.Arg200Pro) VPS33A variant presenting over 12 years of follow-up with some novel clinical features, including fetal ascites (resolved spontaneously), recurrent joint effusion and peripheral edemas, normal growth, and visceral obesity. Functional analyses revealed a slight presence of chondroitin sulphate (only) in urine glycosaminoglycan electrophoresis, presence of sialooligosaccharides in urine by thin-layer chromatography, and normal results of lysosomal enzymes activity and lysosphingolipids concentration in dried blood spot. The comparison with other MPS-PS described cases was also provided. The presented description of the natural history of MPS-PS in our patient may broaden the spectrum of phenotypes in this disease.

Keywords: VPS33A; lysosomal storage disease; mucopolysaccharidosis; mucopolysaccharidosis-plus syndrome.

Publication types

  • Case Reports
  • Comparative Study

MeSH terms

  • Chondroitin Sulfates / urine
  • Glycosaminoglycans / urine
  • Humans
  • Mucopolysaccharidoses* / blood
  • Mucopolysaccharidoses* / diagnosis
  • Mucopolysaccharidoses* / genetics
  • Mucopolysaccharidoses* / urine
  • Mutation
  • Poland
  • Sphingolipids / blood
  • Vesicular Transport Proteins* / genetics

Substances

  • Glycosaminoglycans
  • Sphingolipids
  • VPS33A protein, human
  • Vesicular Transport Proteins
  • Chondroitin Sulfates

Grants and funding

This research received no external funding.